New Investigational Drug's Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and...

Area of Science:

• Oncology
• Medical Research

Background:

• Cervical cancer (CC) remains a significant global health challenge, ranking as the fourth most common cancer in women worldwide.
• Despite advances in screening and treatment, metastatic or recurrent CC presents ongoing therapeutic challenges.
• Palliative chemotherapy is the current standard for patients ineligible for curative treatments like surgery or radiotherapy.

Purpose of the Study:

• To provide a comprehensive and up-to-date review of investigated therapies for cervical cancer management.
• To highlight ongoing clinical trials and research findings in CC treatment.
• To explore novel therapeutic strategies targeting specific molecular pathways.

Main Methods:

• Review of clinical research findings and ongoing trials in cervical cancer therapy.
• Identification and analysis of targeted agents acting on molecular pathways.
• Examination of epigenetic mechanisms in CC treatment.

Main Results:

• Several novel therapeutic agents targeting molecular pathways show promise.
• Targeted agents include those acting on epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), and poly ADP-ribosepolymerase (PARP).
• Epigenetic therapies represent an emerging area of research for CC.

Conclusions:

• Targeted therapies and epigenetic modifications offer promising avenues for cervical cancer management.
• Continued research and clinical trials are crucial for advancing CC treatment strategies.
• Novel agents targeting specific molecular pathways hold potential for improving outcomes in patients with advanced or recurrent CC.